Key clinical point: Faster acting integrase inhibitors have the potential to accelerate reduction of viral load.
Major finding: Three-quarters of patients achieved viral load less than 50 copies/mL at delivery with dolutegravir, compared with 43% receiving efavirenz.
Study details: A randomized, controlled trial (n = 268).
Disclosures: The study was funded by the University of Liverpool. Dr. Khoo reported consulting for and receiving research funding from ViiV.
Khoo S et al. CROI 2019, Abstract 40 LB.